Background

KRAS G12C mutation is a rare alteration found in about 3–4% of colorectal cancer patients worldwide, and it is difficult to achieve sufficient efficacy with the current standard of care, mFOLFOX6 plus bevacizumab (anti‑VEGF antibody). Existing anti‑EGFR antibody cetuximab has limited activity when KRAS is mutated, underscoring the need for personalized therapy. Therefore, a direct inhibition strategy targeting KRAS G12C is gaining attention.

Trial Design

This Phase 3 study is led by Merck and evaluates a strategy that combines Calderasiv (a KRAS G12C inhibitor) and cetuximab (an EGFR inhibitor) with the mFOLFOX6 regimen. The primary objectives are safety assessment and progression‑free survival (PFS) extension, with the control arm receiving standard mFOLFOX6 ± bevacizumab. Enrollment started in July 2025 and the trial will be conducted at multiple sites worldwide.

Differentiation

Calderasiv selectively blocks the KRAS G12C mutant, directly shutting down a key tumor growth signal. Adding cetuximab further suppresses the EGFR pathway, potentially minimizing resistance to KRAS inhibition. This combination is expected to yield higher response rates than EGFR inhibitor monotherapy.

Market and Industry Impact

If successful, this would be the first regimen to combine a KRAS G12C‑targeted therapy with anti‑EGFR treatment in colorectal cancer, potentially commercializing a novel therapeutic class. The impact would be positive for both the KRAS G12C inhibitor market (estimated $500–600 million in 2024) and the colorectal cancer treatment market (approximately $2.5 billion annually). Competitors such as Amgen and Mirati could also feel increased pressure on their pipelines.

Risks and Outlook

The trial is currently in the enrollment phase, and final results are expected to take at least three years. Safety concerns or modest PFS improvement could dampen enthusiasm for KRAS G12C inhibitors. Conversely, positive data would substantially strengthen Merck’s portfolio and restore investor confidence.